[vc_row][vc_column][vc_column_text] Reprinted with permission from the Foundation Fighting Blindness Blog Ophthotech, a biopharmaceutical company developing therapies for eye diseases, has enrolled the first patient in its Phase 2b clinical trial of Zimura® for people with Stargardt disease caused by mutations in the gene ABCA4. The 120-participant study will be taking place at more than 30 sites. Data and… Continue reading Ophthotech Launching Human Study of Emerging Therapy for Stargardt Disease
Colorado Low-Vision Service and Care